{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer", "query": { "condition": "Her 2 Positive Breast Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 242, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T06:12:47.523Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00640861", "title": "Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "CpG oligodeoxynucleotide", "type": "BIOLOGICAL" }, { "name": "HER-2/neu peptide vaccine", "type": "BIOLOGICAL" }, { "name": "MUC-1 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 45, "start_date": "2008-08-28", "completion_date": "2015-04-21", "has_results": false, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00640861" }, { "nct_id": "NCT01526473", "title": "A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2+ Cancer" ], "interventions": [ { "name": "AVX901", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Kim Lyerly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-02", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526473" }, { "nct_id": "NCT00524277", "title": "Vaccine Therapy in Treating Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GP2 peptide + GM-CSF vaccine", "type": "BIOLOGICAL" }, { "name": "GM-CSF (sargramostim)", "type": "BIOLOGICAL" }, { "name": "AE37 + GM-CSF vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "San Antonio Military Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 456, "start_date": "2007-01", "completion_date": "2017-03-31", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 11, "location_summary": "Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524277" }, { "nct_id": "NCT02049957", "title": "Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 118, "start_date": "2014-02-13", "completion_date": "2018-06-29", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 30, "location_summary": "Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049957" }, { "nct_id": "NCT07310420", "title": "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "ZOLADEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TerSera Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 88, "start_date": "2026-06-30", "completion_date": "2027-03-30", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 11, "location_summary": "Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 8 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Lisle", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07310420" }, { "nct_id": "NCT01674140", "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1939, "start_date": "2013-09-12", "completion_date": "2030-01", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 1455, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674140" }, { "nct_id": "NCT04460911", "title": "Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2019-10-19", "completion_date": "2022-04-01", "has_results": true, "last_update_posted_date": "2024-01-11", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460911" }, { "nct_id": "NCT01754519", "title": "Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ductal Breast Carcinoma In Situ", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Cribriform Breast Carcinoma", "Invasive Ductal Carcinoma, Not Otherwise Specified", "Lobular Breast Carcinoma In Situ", "Mucinous Breast Carcinoma", "Papillary Breast Carcinoma", "Progesterone Receptor Positive", "Stage I Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIC Breast Cancer", "Tubular Breast Carcinoma" ], "interventions": [ { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2013-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-07-07", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01754519" }, { "nct_id": "NCT00524303", "title": "Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FEC75", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2007-08", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 23, "location_summary": "Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hudson", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524303" }, { "nct_id": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07248144", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-08-05", "completion_date": "2030-11-04", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-26T06:12:47.523Z", "location_count": 102, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07062965" } ] }